Sunzen Biotech on track to return to the black

Top management: Teo (left) and Ching at the group’s headquarter in Shah Alam. They are very positive about Sunzen’s business outlook.

Sunzen Biotech Bhd is on track to break even this year and aims to achieve profitability in 2022, after incurring losses for three years, according to group managing director and CEO Teo Yek Ming.

Teo tells StarBizWeek that in the near term, the group is optimistic about growing profits for its traditional Chinese medicine, herbal health foods and beverages and bird’s nest segment as well as the recently acquired small and medium enterprise loan financing unit.

Limited time offer:
Just RM5 per month.

Monthly Plan


Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan


Billed as RM148.00/year

1 month

Free Trial

For new subscribers only

Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Nasdaq, S&P set to open higher on tech boost, earnings glee
Sasbadi reports highest ever quarterly revenue
Aneka Jaringan leverages order book for growth
Chin Hin Group to develop two lands with combined GDV of RM1.08bil
CLMT 1Q net profit rises to RM33.49mil on higher occupancies, positive rental reversions
Ringgit ends marginally lower on firmer US dollar index
MoF: Govt to establish high-level facilitation platform to oversee potential, approved strategic investments
Meta Bright signs RM24mil leasing contract with Australia company
OCR Group to develop RM313mil residential project in Rawang
Legacy Credit emerges as substantial shareholder in VCI Global

Others Also Read